Novel Findings Support Original Categorization of HER2

This article originally appeared here.
Share this content:
Novel Findings Support Original Categorization of <i>HER2</i>
Novel Findings Support Original Categorization of HER2

THURSDAY, Sept. 1, 2016 (HealthDay News) -- The original classifications of human epidermal growth factor receptor 2 (HER2) categorization by fluorescent in situ hybridization (FISH) have been supported by recent data, according to a report published online Aug. 29 in the Journal of Clinical Oncology.

Michael F. Press, M.D., from the University of Southern California Norris Comprehensive Cancer Center in Los Angeles, and colleagues reevaluated the HER2 FISH status of patients from Breast Cancer International Research Group (BCIRG)-005/006/007 clinical trials according to current American Society of Clinical Oncology and the College of American Pathologists (ASCO-CAP) guidelines, which designate five groups based on HER2 FISH ratio and average HER2 gene copy number per tumor cell. Data were included for 10,468 patients.

The researchers found that of the patients included in the trial, 40.8, 0.7, 0.5, 4.1, and 53.9 percent were in ASCO-CAP in-situ hybridization (ISH) groups 1, 2, 3, 4, and 5, respectively. Similar distributions were seen in screened and accrued subpopulations. Among accrued patients, there was a strong correlation for FISH group 1 breast cancers with immunohistochemistry 3+ status; groups 2, 4, and 5 were strongly correlated with immunohistochemistry 0/1+ status. Among patients accrued to BCIRG-005, compared with group 5, group 4 was not associated with significantly worse disease-free survival or overall survival. Among patients accrued to BCIRG-006, significant benefit from trastuzumab therapy was seen for group 1 but not group 2.

"Our findings support the original categorizations of HER2 by FISH status in BCIRG/Translational Research in Oncology trials," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »